Statins, haemostatic factors and thrombotic risk

Vanessa Bianconi, Amirhossein Sahebkar, Maciej Banach, Matteo Pirro

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)


PURPOSE OF REVIEW: Statins reduce cholesterol synthesis and promote low-density lipoprotein clearance from circulation. Beyond their cholesterol-lowering action, statins may interfere with haemostasis. This review aims to provide an update on the impact of statin treatment on markers of haemostasis and platelet function and on thrombosis-related outcomes. RECENT FINDINGS: Different coagulation factors are modulated by statins, leading to inhibition of coagulation and increased fibrinolysis. Also, an impact of statins on platelet function has been documented. From a clinical perspective, several observational studies have revealed a reduced incidence of venous thromboembolism in patients receiving statins, which has been argued in some available studies and meta-analyses. Furthermore, a beneficial effect of early statin initiation following acute coronary syndrome for short-term prevention of thrombosis-related events has been documented, but the available data are still not consistent. SUMMARY: Although statins influence the levels of a multitude of haemostatic factors in an antithrombotic direction, data supporting their use for venous thromboembolism prevention are not consistent, and the impact of statins on early vascular events following acute coronary syndrome is still debated. Whether the robust long-term beneficial effects of statins in reducing cardiovascular risk may be also explained by persistent changes in haemostatic factors needs further exploration.

Original languageEnglish
Pages (from-to)460-466
Number of pages7
JournalCurrent Opinion in Cardiology
Issue number4
Publication statusPublished - 1 Jul 2017


Dive into the research topics of 'Statins, haemostatic factors and thrombotic risk'. Together they form a unique fingerprint.

Cite this